SIMULTANEOUS ESTIMATION OF NORFLOXACIN AND TINIDAZOLE IN COMBINED TABLET DOSAGE FORM BY USING RP- HPLC METHOD
HTML Full TextSIMULTANEOUS ESTIMATION OF NORFLOXACIN AND TINIDAZOLE IN COMBINED TABLET DOSAGE FORM BY USING RP- HPLC METHOD
Mrunal Bulbule and Deepali Gangrade *
Vivekanand Education Society’s College of Pharmacy, Mumbai University, Chembur (E), Mumbai, Maharashtra, India.
ABSTRACT: Simultaneous estimation method for Norfloxacin and Tinidazole in tablet dosage form had been developed by RP- HPLC. Both the drugs come under the category of antimicrobials and prescribed frequently in combination. The developed method is a gradient method which gives retention time of Norfloxacin and Tinidazole as 3.8min and 4.8min respectively. The separation was carried out on Supelco C18 (25cm × 4.6mm, 5µ) column using 0.05M phosphate buffer (pH 3 adjusted with ortho- phosphoric acid) and acetonitrile as a mobile phase. The flow rate was 0.8mL/min and wavelength used was 300nm. The method was validated as per ICH guideline and found to be linear between the range of 1- 6µg/mL for Norfloxacin and 1.5- 9µg/mL for Tinidazole. The developed method was found to be rapid, accurate and reproducible and therefore can be applied for simultaneous estimation of both the drugs as API or tablet dosage form effectively.
Keywords: |
RP- HPLC, Gradient method, Simultaneous, Norfloxacin, Tinidazole
INTRODUCTION: Now a day’s lot of drugs come in the market as in combination form, which creates difficulty to the analyst for their estimation and also estimation of related substances likely to be present in those dosage formulations. This research focuses onto the simultaneous estimation of Norlfoxacin and Tinidazole in API or combined tablet form by RP- HPLC.
Drug profile:
- Norfloxacin:
It is a first generation synthetic flouroquinolone which is used as a synthetic chemotherapeutic antibacterial agent 1, 2. It is used to treat common as well as complicated urinary tract infections 3.
Molecular Formula: C16H18FN3O3
Molecular Formula: C16H18FN3O3
Chemical Name: 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3 quinolinecarboxylic acid
Molecular Weight: 319.33 g/mol
Description: White to light-yellow crystalline powder
Solubility: Slightly soluble in ethanol, methanol. Very slightly soluble in water.
Melting Point: 220-221 °C
Category: Antibacterial
Mechanism of action: It is a broad spectrum antibiotic showing activity against gram negative and gram positive bacteria. It inhibits bacterial cell division by inhibiting DNA gyrase, topoisomerase II and IV which are necessary enzymes for causing separation of bacterial DNA 4. A number of methods like capillary electrophoresis 5, HPLC 6, TLC 7, LC 8, voltammetry 9, ISE 10, differential pulse polarography 11, fluorimetry 12 and potentiometric titration 13 have been widely used for the detection in pharmaceuticals.
- Tinidazole: It is a derivative of 2-methylimidazole, which belongs to the class of nitroimidazole antibiotics. It is an anti-parasitic drug and used for a treatment of various amoebic and parasitic infections 14.
Molecular Formula: C8H13N3O4S
Chemical Name: 1-(2- ethylsulfonylethyl)-2-methyl-5-nitro-imidazole
Molecular Weight: 247.27 g/mol
Description: White or pale yellow crystalline powder
Solubility: Practically insoluble in water, soluble in aetone and in methylene chloride, sparingly soluble in methanol
Melting Point: 127-128 °C
Category: Antiprotozoal, Antibacterial
Mechanism of action: Tinidazole is a prodrug and antiprotozoal agent. The nitro group of Tinidazole is reduced in Trichomonas by a ferredoxin- mediated electron transport system. The free nito radical generated as a result of this reduction is believed to be responsible for the antiprotozoal activity. It is suggested that the toxic free radicals covalently bind DNA, causing DNA damage and leading to cell death. The mechanism by which Tinidazole exhibits activity against Giardia and Entamoeba species is not known, though it is probably similar.
Literature survey reveals that Tinidazole is official in USP 15 and BP 16. Tinidazole was determined by high performance liquid chromatography 17, spectrophotometry 18, voltammetry 19, capillary electrophoresis 20, flow injection analysis 21 and gas chromatography with FID 22.
Objective:
- To develop a RP-HPLC assay method for the estimation of Norfloxacin and Tinidazole.
- To validate the developed RP-HPLC method as per ICH guidelines.
- To apply the developed RP-HPLC method on marketed formulation.
MATERIALS AND METHODS:
Instrumentation: This research was carried out on Shimadzu HPLC with the help of the software ‘LC solution’. All the glass wares used were of ‘A’ grade.
Reagents and chemicals: The API of Norfloxacin was obtained from Cipla Pvt. Ltd. Vikhroli, Mumbai and Tinidazole was obtained from Aarti Pharma, Mumbai as a gift sample. The tablet formulation used was of a brand name ‘Nor-TZ’ containing norfloxacin (400mg) and tinidazole (600mg). All other chemicals used were of HPLC grade.
Instrumentation:
TABLE 1: INSTRUMENTS USED
S.no. | Name of the instrument | Company |
1 | HPLC | Shimadzu |
2 | Weighing balance | Premier weighing system |
3 | pH meter | DBK Digital pH meter |
4 | Sonicator | Oscar |
Preparation of 0.05 M Potassium dihydrogen orthophosphate (pH 3.0): Accurately weighed 6.80 g of Potassium dihydrogen orthophosphate, dissolved in 1000 ml of water and adjusted the pH with o-phosphoric acid to 3.0 ± 0.05. The solution was filtered using 0.45 µ membrane filter.
Preparation of Mobile Phase: Phosphate buffer was prepared using Potassium dihydrogen orthophosphate (0.05 M) and pH was adjusted to 3.0 with Orthophosphoric acid. Then it was sonicated and filtered using 0.45 µ membrane filter. Different ports were used for buffer and acetonitrile to run the gradient mobile phase.
Preparation of diluents: 0.05M Phosphate buffer (ph=3.0) and acetonitrile were mixed accurately in the ratio of 50:50 (v/v) and degassed by sonication.
Preparation of standard stock solution (Norfloxacin 400 µg/ml and Tinidazole 600 µg/ml): About 40 mg of Norfloxacin and 60 mg of Tinidazole were accurately weighed and transferred into 100 ml volumetric flask respectively. The solution was sonicated to dissolve and diluted up to the volume with the diluent and filtered thrugh 0.45µ membrane filter for interference free solution.
Preparation of standard solution (Norfloxacin 4 µg/ml and Tinidazole 6 µg/ml): About 1 ml of standard stock solution was transferred into 100 ml volumetric flask and diluted up to the volume with diluent and the solution was then filtered through 0.45 µm membrane filter.
Preparation of Sample stock solution (Norfloxacin 400µg/ml and Tinidazole 600µg/ml): For sample stock preparation, tablet containing combination of Norfloxacin and Tinidazole was taken. Total 10 tablets were weighed and quantity equivalent to 400mg of Norfloxacin and 600mg of Tinidazole was weighed. This is transferred to 1000mL volumetric flask. Make up the volume with the diluents to prepare solution containing 400µg/mL of Norfloxacin and 600 µg/mL of Tinidazole.
Preparation of Sample Solution (Norfloxacin 4µg/ml and Tinidazole 6µg/ml): From the above stock solution 1mL was transferred in 100mL volumetric flask and diluted upto the mark with the diluent to prepare 4 µg/mL of Norfloxacin and 6 µg/mL of Tinidazole.
Final method:
Reagents:
- Potassium dihydrogen orthophosphate (AR grade)
- Orthophosphoric acid (GR grade)
- Water (HPLC grade or equivalent)
- Acetonitrile (HPLC grade)
TABLE 2: CHROMATOGRAPHIC CONDITIONS
Column | Supelco C18 (25cm X 4.6mm X 5µ) |
Wavelength | 300 nm |
Flow Rate | 0.8 ml/min |
Column Oven Temperature | 30 °C |
Run time | 7 minutes |
Injection Volume | 10 µl |
Retention time of Norfloxacin | 3.8 minutes |
Retention time of Tinidazole | 4.8 minutes |
Mobile Phase (Gradient)
A: 0.05M Phosphate buffer (pH=3 adjusted with OPA)
B: Acetonitrile (HPLC grade)
|
Time(min) A% B%
0.01 60 40 2.5 90 10 3.5 70 30 4.0 60 40 7.0 60 40 7.01 Controller Stop |
Method Validation: 23
Specificity: To ensure the absence of interference from blank in Norfloxacin and Tinidazole drug product. One blank solution of diluent was injected and Norfloxacin and Tinidazole were injected individually.
Acceptance criteria: There should be no interference from blank at the retention time of Norfloxacin and Tinidazole.
Accuracy: To evaluate the recovery at each level. Working standards of the drugs were prepared at three different concentrations (levels) 80 %, 100 % and 120 %. The measurements were done in triplicates. For Norfloxacin 4µg/mL was considered as 100%, therefore 80% became 3.2µg/mL and 120% of 4.8µg/mL. About 0.8mL, 1
ml and 1.2mL of standard stock solution was transferred into different 100 ml volumetric flasks and diluted up to the volume with diluent for preparing 80%, 100% and 120% solutions respectively.
Acceptance criteria: Individual % recovery of Norfloxacin and Tinidazole at each level should be between 98% - 102% and % RSD should not be more than 2.0 at each level.
Precision:
System precision: Prepared and injected six replicates of standard solution as per the proposed method of analysis into HPLC system. Calculated the mean, SD and % RSD for peak areas of Norfloxacin and Tinidazole. Standard solution was of 4µg/mL Norfloxacin and 6µg/mL of Tinidazole mixture.
Method precision: Six samples of same strength as that of standard solution of Norfloxacin and Tinidazole were prepared and analyzed as per the test method. The % assay and % RSD for Norfloxacin and Tinidazole in six samples was calculated.
Intermediate precision or Ruggedness:
Ruggedness of the method was verified by analyzing six samples of the same concentration used for method precision as per proposed method by different analysts, different column serial number on different day. The % assay and % RSD of Norfloxacin and Tinidazole in tablets was determined.
Acceptance criteria: % RSD and cumulative % RSD should not be more than 2.0 and % assay should be within the specification limit.
Linearity: Linearity of Norfloxacin and Tinidazole was performed using standard solution in the range of 1-6 µg/ml and 1.5- 9 µg/ml for RP- HPLC.
Acceptance criteria: Correlation coefficient (R2) should be not less than 0.999.
Range: For range, data shall be considered from linearity and accuracy.
Acceptance criteria: Correlation coefficient (R2) should be not less than 0.999 and individual % recovery of Norfloxacin and Tinidazole at each level should be between 98 % - 102 %.
Robustness: Robustness of the method was evaluated by changing the flow rate by ± 10 %, by changing the column temperature by ± 5 °C and by changing the pH of buffer by ± 0.1 units.
Acceptance criteria: % RSD should be not more than 2.0
LOD (Detection limit): The detection limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be detected but not necessarily quantitated as an exact value. For assay purpose limit of detection was not considered as the validation parameter as per ICH guideline.
LOQ: The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a parameter of quantitative assays for low levels of compounds in sample matrices, and is used particularly for the determination of impurities and/or degradation products. Therefore this is not considered as the validation parameter for assay purpose.
RESULT AND DISCUSSION: Before validation of the developed method, analysis of blank solution (only mobile phase), standard solution (mixed standard) and sample solution (tablet mixture) was carried out. Following were the results obtained.
Blank Solution:
FIG. 1: CHROMATOGRAM OF BLANK SOLUTION
Observation: It was found that the blank solution does not show any interference of characteristic peak and therefore can be used for estimation of drugs.
Standard Solution:
FIG. 2: CHROMATOGRAM OF STANDARD SOLUTION (NORFLOXACIN 4µg/mL AND TINIDAZOLE 6 µg/mL)
Sample Solution:
FIG. 3: CHROMATOGRAM OF SAMPLE SOLUTION (NORFLOXACIN 4µg/mL AND TINIDAZOLE 6 µg/mL)
Method validation: Specificity: Chromatograms of blank solution i.e. diluent and Norfloxacin and Tinidazole individually were compared.
DISCUSSION: From above chromatograms it was found that there were no interferences from the blank solution at the retention time of Norfloxacin and Tinidazole. Therefore it was concluded that the method was specific for the detection of Norfloxacin and Tinidazole.
Accuracy: Initially a standard solution was analyzed and for accuracy studies, 80%, 100% and 120% solutions of sample were prepared. From these areas of Norfloxacin and Tinidazole at all 3 concentrations were considered for the calculations and amount found was compared with the amount added for preparing these concentrations.
TABLE 3: ACCURACY STUDIES OF NORFLOXACIN
Level | Amount taken (mg) | Area | % Recovery | Mean % recovery | Amount found (mg) | %RSD |
I (80%) | 3200 | 149462 | 100.24 | 100.10%
|
3203.2 | 0.18%
|
3200 | 149358 | 100.17 | 3205.4 | |||
3200 | 148960 | 99.90 | 3196.8 | |||
II (100%) | 4000 | 187106 | 100.35 | 100.36%
|
4014.4 | 0.03%
|
4000 | 187211 | 100.40 | 4016 | |||
4000 | 187100 | 100.34 | 4013.6 | |||
III (120%) | 4800 | 222710 | 99.59 | 99.48%
|
4780.3 | 0.19%
|
4800 | 222721 | 99.60 | 4780.8 | |||
4800 | 221988 | 99.27 | 4764.9 |
TABLE 4: ACCURACY STUDIES OF TINIDAZOLE
Level | Amount taken (mg) | Area | % Recovery | Mean % recovery | Amount found (mg) | %RSD |
I (80%) | 4800 | 50771 | 100.70 | 100.69%
|
4833.6 | 0.11%
|
4800 | 50825 | 100.80 | 4838.4 | |||
4800 | 50712 | 100.58 | 4827.8 | |||
II (100%) | 6000 | 63659 | 101.06 | 101.14%
|
6063.6 | 0.10%
|
6000 | 63741 | 101.16 | 6069.6 | |||
6000 | 63779 | 101.22 | 6073.2 | |||
III (120%) | 7200 | 74925 | 99.06 | 99.30%
|
7132.3 | 0.21%
|
Discussion:
- % Recovery of Norfloxacin was found to be in the range of 99.48%- 100.10% and %RSD was found to be between 0.03%- 0.19%.
- % Recovery of Tinidazole was found to be in the range of 99.30%- 101.14% and %RSD was found to be between 0.10%- 0.21%.
- From the above observation it was concluded that the method is accurate for the simultaneous determination of Norfloxacin and Tinidazole in a tablet dosage form.
Precision: Precision was performed in three different levels as system precision, method precision and intermediate precision i.e. ruggedness.
System precision: System precision was performed by injecting six replicates of standard solution of 10µg/mL.
TABLE 5: RESULTS OF SYSTEM PRECISION
Drug Name | Sr. No. | Area | Mean | %RSD |
Norfloxacin | 1 | 186452 |
186142.5
|
0.37%
|
2 | 186880 | |||
3 | 186289 | |||
4 | 184929 | |||
5 | 185855 | |||
6 | 186450 | |||
Tinidazole | 1 | 63551 |
63660.5
|
0.25%
|
2 | 63762 | |||
3 | 63924 | |||
4 | 63577 | |||
5 | 63650 | |||
6 | 63499 |
Discussion: The % RSD values indicate an acceptable level of precision of the analytical system for the assay of Norfloxacin and Tinidazole. The % RSD values on lower side indicate that there exists only minimum variation in the results and thus the system precision is validated.
Method precision: Method precision was performed by injecting six samples of same strength as that of standard solution of Norfloxacin and Tinidazole (10µg/ mL). Results obtained were as follows:
TABLE 6: RESULTS OF METHOD PRECISION
Drug Name | Sr. No. | Area | Mean | %RSD |
Norfloxacin | 1 | 187241 |
187265.5
|
0.06%
|
2 | 187168 | |||
3 | 187359 | |||
4 | 187294 | |||
5 | 187105 | |||
6 | 187426 | |||
Tinidazole | 1 | 64658 |
64434.17
|
0.61%
|
2 | 64853 | |||
3 | 63765 | |||
4 | 64684 | |||
5 | 64359 | |||
6 | 64286 |
Intermediate precision (Ruggedness): For intermediate precision different analyst on different day analysis was carried out.
TABLE 7: PARAMETERS FOR INTERMEDIATE PRECISION
Sr. no. | Parameter | Specification |
1. | Different analyst | Analyst II |
2. | Different day | Interday precision |
TABLE 8: % RSD CALCULATIONS FOR INTERMEDIATE PRECISION
Drug Name | Sr. No. | Area | Mean | %RSD |
Norfloxacin | 1 | 187049 |
187142.7
|
0.04%
|
2 | 187137 | |||
3 | 187164 | |||
4 | 187281 | |||
5 | 187098 | |||
6 | 187127 | |||
Tinidazole | 1 | 63941 |
63914.5
|
0.76%
|
2 | 64268 | |||
3 | 63671 | |||
4 | 63467 | |||
5 | 64684 | |||
6 | 63456 |
Discussion: The % RSD values for intermediate precision were found to be within the specified limit. This indicated that the method is rugged and can be used to analyze the formulations containing Norfloxacin and Tinidazole effectively in any given condition.
Linearity: Linearity studies were performed at six different concentrations. The linearity data was calculated on individual drug basis and checked for the R2 value.
FIG.4: LINEARITY PLOT OF NORFLOXACIN
FIG.5: LINEARITY PLOT OF TINIDAZOLE
Discussion: The correlation coefficient (R2) values for Norfloxacin and Tinidazole were found to be within acceptable limits. This indicated that the method is linear between the concentrations 1 µg/ml and 6 µg/ml for Norfloxacin and 1.5 µg/ml and 9 µg/ml for Tinidazole.
Range: It was inferred from the data of accuracy and linearity that the established range for the estimation of Norfloxacin and Tinidazole was between the concentration range of 25 % to 150 %. Thus, the range was established as 1 µg/ml and 6µg/ml for Norfloxacin and 1.5 µg/ml and 9 µg/ml for Tinidazole.
Robustness: Deliberate variations were made in the method and the % RSD was calculated. Plus flow rate, minus flow rate, plus pH, minus pH, plus temperature and minus temperature were the variations that were analyzed.
TABLE 9: ROBUSTNESS OF NORFLOXACIN
Sr. No. | Parameter | Area | Mean | %RSD |
1 | Plus pH (3.1) | 187046 |
187055.3
|
0.01%
|
187083 | ||||
187037 | ||||
2 | Minus pH (2.9) | 187098 |
187085
|
0.01%
|
187076 | ||||
187081 | ||||
3 | Plus Temperature
(35°C) |
187214 |
187245
|
0.02%
|
187245 | ||||
187276 | ||||
4 | Minus Temperature
(25°C) |
187286 |
187264
|
0.01%
|
187257 | ||||
187249 | ||||
5 | Plus Flow (0.9mL/min)
|
187135 |
187144
|
0.01%
|
187168 | ||||
187129 | ||||
6 | Minus Flow
(0.7mL/min)
|
187245 |
187253.3
|
0.01%
|
187267 | ||||
187248 |
TABLE 10: ROBUSTNESS OF TINIDAZOLE
Sr. No. | Parameter | Area | Mean | %RSD |
1 | Plus pH (3.1) | 64821 |
64809.3
|
0.06%
|
64764 | ||||
64843 | ||||
2 | Minus pH (2.9) | 64673 |
64794.3
|
0.21%
|
64764 | ||||
64946 | ||||
3 | Plus Temperature
(35°C) |
64483 |
64781.6
|
0.41%
|
64975 | ||||
64887 | ||||
4 | Minus Temperature
(25°C) |
64798 |
64888
|
0.16%
|
64999 | ||||
64867 | ||||
5 | Plus Flow (0.9mL/min)
|
64523 |
64313.3 |
0.29%
|
64258 | ||||
64159 | ||||
6 | Minus Flow
(0.7mL/min)
|
64486 |
64538.3
|
0.30%
|
64376 | ||||
64753 |
Discussion: Small but deliberate variations were made in the method parameters and it was found that % RSD values for all the variations were in acceptable limits. This indicated that the method is robust and that it can be used within small variations of flow rate, pH and temperature without having a major effect on the results of % assay values.
CONCLUSION: The method was developed and validated which concluded that the method is linear, simple, accurate, precise and rugged. Thus, the proposed method can be effectively applied for analysis of Norfloxacin and tinidazole in bulk dosage forms as well as in combined tablet dosage form.
ACKNOWLEDGEMENT: The authors are thankful to Vivekanand Education Society’s College of Pharmacy, Chembur (E), Mumbai for providing all the necessary facilities required for the research work. The authors are also thankful to all the teaching and non-teaching staff and the colleagues for their constant support. Hearty thanks to our parents. Also authors are very thankful to Aarti Drugs Limited and Cipla Limited for providing gift samples.
REFERENCES:
- Nelson J, Chiller T, Powers J: Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story. Clin Infect Dis 2007; 44 (7): 977–980.
- Padeĭskaia E: Norfloxacin: more than 20 years of clinical use, the results and place among fluoroquinolones in modern chemotherapy for infections. Antibiot Khimioter 2003; 48(9): 28–36.
- Rafalsky V, Andreeva I, Rjabkova V: Quinolones for uncomplicated acute cystitis in women. Cochrane Database Syst Rev 2006; 3(3).
- Drlica K, Zhao X: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997; 61(3): 377–392.
- Yang Z, Wang X, Qin W, Zhao H: Capillary electrophoresis-chemiluminescence determination of norfloxacin and prulifloxacin. Anal Chim. Acta 2008; 623 (2): 231.
- Ghanti M, Pannu H, Loni A: Development and validation of ARP–HPLC method for simultaneous estimation of metronidazole and norfloxacin in bulk and tablet dosage form. of Pharm. And Pharmaceutical Sciences 2012; 4 (4): 241.
- Wang P, Feng Y, Chen L: Simultaneous Determination of Trace Norfloxacin, Pefloxacin, and Ciprofloxacin by TLC Fluorescence Spectrodensitometry. Microchemical J 1997; 56 (2): 229-235.
- Lee H, Peart T, Svoboda M: Determination of ofloxacin, norfloxacin and ciprofloxacin in sewage by selective solid-phase extraction, liquid chromatography with fluorescence detection and liquid chromatography- tandem mass spectrometry. J. Chromatography A 2007; 1139: 45- 52.
- Ghoneim M, Radi A, Beltagi A: Determination of Norfloxacin by square-wave adsorptive voltammetry on a glassy carbon electrode. Pharm. And Biomed. Anal 2001; 25 (2): 205- 10.
- Zhang S, He C, Wang L: Preparation and application of an ion selective electrode for norfloxacin. Fenxi Shiyanshi. 1999; 18 (4): 95.
- Jaber A, Lounici A: Adsorptive differential-pulse stripping voltammetry of norfloxacin and its analytical application. Analyst 1994; 119 (11): 2351.
- Vleiopoulo C, Ioannou P, Lianidou E: Application of terbium sensitized fluorescence for the determination of fluoroquinolone antibiotics pefloxacin, ciprofloxacin and norfloxacin. Pharm. Biomed. Anal 1997; 15 (12): 1839.
- Mandil H, Sakur A, Nasser B: Use of Cerium (IV) in Potentiometric Titration of Norfloxacin in Pharmaceutical Preparations. Asian Journal of Chemistry 2012; 24 (7): 2985.
- Ebel K, Koehler H, Gamer A, Jäckh R: Imidazole and Derivatives. Ullmann’s Encyclopedia of Industrial Chemistry 2002; 13: 661.
- The United States Pharmacopoeia, the National Formulary, USD XXII, 1990.
- The British Pharmacopœia, Her Majesty's Stationery Office Ltd., London, 2007.
- Halkar U, Ankalkope P: Reverse phase highperformance liquid chromatographic determination of ofloxacin and tinidazole in tablets. Indian Drugs. 2000; 37 (12): 585-588.
- Tipre D, Kasture A: Simultaneous estimation of ciprofloxacin and tinidazole in tablet dosage forms using spectrophotometric and HPLC methods. Indian Drugs. 2000; 37 (3): 148- 154.
- Warowna M, Fijalek Z, Dziekanska A, Korzeniewska A: Determination of imidazole derivatives in pharmaceutical formulations using electrochemical methods. I. Metronidazole, tinidazole and ornidazole. Acta Poloniae Pharmaceutica. 1991; 48 (3-4): 17-21.
- Alnajjar A, Abuseada H, Idris A: Capillary electrophoresis for the determination of norfloxacin and tinidazole in pharmaceuticals with multi-response optimization. Talanta. 2007; 72 (2): 842-846.
- Mohamed M, El-gendy A, El-bardicy M, Tawakkol M, Ahmad A: Flow-injection analysis of pharmaceutical compounds. VII. Determination of some anthelmintic and antiprotozoal compounds. Spectroscopy Letters. 1996; 29 (2): 299-319.
- Sadana G, Gaonkar M: Simultaneous GLC determination of diloxanide furoate and tinidazole in pharmaceutical dosage forms. Indian Drugs. 1989; 26 (5): 241-246.
- ICH guidelines, Validation of analytical procedures: text and methodology, Q2A (R1) Nov; 2005.
How to cite this article:
Bulbule M and Gangrade D: Simultaneous estimation of Norfloxacin and Tinidazole in combined tablet dosage form by using RP- HPLC method. Int J Pharm Sci Res 2017; 8(1): 236-43.doi: 10.13040/IJPSR.0975-8232.8(1).236-43.
All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
Article Information
31
236-243
535
1593
English
IJPSR
Mrunal Bulbule and Deepali Gangrade *
Vivekanand Education Society’s College of Pharmacy, Mumbai University, Chembur (E), Mumbai, Maharashtra, India
deepali.gangrade@ves.ac.in
15 July, 2016
22 August, 2016
13 September, 2016
10.13040/IJPSR.0975-8232.8(1).236-43
01 January, 2017